Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.392
K. Álvarez Tosco, C. Fraile Clemente, C. Pérez Martín, I. González García, CL Díaz Díaz, P. Joy Carmona, A. Martín López, J. Merino Alonso
Malnutrition is one of the stron-gest predictors of mortality and morbidity in haemodialysis patients. Albumin levels are used as an indicator of its severity and concentrations under 3.8 g/dL indicate severe malnutrition. As first-line treatment, guidelines recommend nutritional counselling and oral nutrition supplements. Furthermore, parenteral nutrition during regular haemodialysis sessions, known as intradialytic parenteral nutrition (IDPN), is an option for patients who can nottolerate oral or enteral routes for nutrition supplements.
{"title":"4CPS-100 Intradialytic parenteral nutrition effects on albumin levels in malnourished haemodialysis patients","authors":"K. Álvarez Tosco, C. Fraile Clemente, C. Pérez Martín, I. González García, CL Díaz Díaz, P. Joy Carmona, A. Martín López, J. Merino Alonso","doi":"10.1136/ejhpharm-2022-eahp.392","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.392","url":null,"abstract":"Malnutrition is one of the stron-gest predictors of mortality and morbidity in haemodialysis patients. Albumin levels are used as an indicator of its severity and concentrations under 3.8 g/dL indicate severe malnutrition. As first-line treatment, guidelines recommend nutritional counselling and oral nutrition supplements. Furthermore, parenteral nutrition during regular haemodialysis sessions, known as intradialytic parenteral nutrition (IDPN), is an option for patients who can nottolerate oral or enteral routes for nutrition supplements.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130439368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.407
A. López-García, N. Herranz-Muñoz, I. Salvador-Llana, P. Sanmartín-Fenollera, M. Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C. Martínez-Nieto, A. Onteniente-González, LM Bedoya-del-Olmo, I. Iglesias-Peinado, J. Sánchez-Rubio-Ferrández
Á López-García*, N Herranz-Muñoz, I Salvador-Llana, P Sanmartín-Fenollera, M VélezDíaz-Pallarés, JA Peña-Pedrosa, C Martínez-Nieto, A Onteniente-González, LM BedoyaDel-Olmo, I Iglesias-Peinado, J Sánchez-Rubio-Ferrández. Hospital Universitario de Getafe, Pharmacy Department, Getafe, Spain; Hospital Universitario Fundación Alcorcón, Pharmacy Department, Alcorcón, Spain; Hospital Universitario Ramón y Cajal, Pharmacy Department, Madrid, Spain; Hospital Clínico San Carlos, Pharmacy Department, Madrid, Spain; Hospital Universitario de La Princesa, Pharmacy Department, Madrid, Spain; Universidad Complutense de Madrid, Facultad de Farmacia, Madrid, Spain
{"title":"4CPS-237 Measuring adherence to antiretroviral treatment: correlation and concordance between two indirect methods","authors":"A. López-García, N. Herranz-Muñoz, I. Salvador-Llana, P. Sanmartín-Fenollera, M. Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C. Martínez-Nieto, A. Onteniente-González, LM Bedoya-del-Olmo, I. Iglesias-Peinado, J. Sánchez-Rubio-Ferrández","doi":"10.1136/ejhpharm-2022-eahp.407","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.407","url":null,"abstract":"Á López-García*, N Herranz-Muñoz, I Salvador-Llana, P Sanmartín-Fenollera, M VélezDíaz-Pallarés, JA Peña-Pedrosa, C Martínez-Nieto, A Onteniente-González, LM BedoyaDel-Olmo, I Iglesias-Peinado, J Sánchez-Rubio-Ferrández. Hospital Universitario de Getafe, Pharmacy Department, Getafe, Spain; Hospital Universitario Fundación Alcorcón, Pharmacy Department, Alcorcón, Spain; Hospital Universitario Ramón y Cajal, Pharmacy Department, Madrid, Spain; Hospital Clínico San Carlos, Pharmacy Department, Madrid, Spain; Hospital Universitario de La Princesa, Pharmacy Department, Madrid, Spain; Universidad Complutense de Madrid, Facultad de Farmacia, Madrid, Spain","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121534885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.382
E. Wilhelmi, C. Salazar, R. Farré, M. Duero, A. Machinena, M. Gómez
Background and importance Liposomal amphotericin B (ANBL) is an effective and safe treatment, however non-IgE-mediated hypersensitivity reactions have been described. Aim and objectives To describe the ANBL desensitisation protocol in a patient with leishmaniasis who developed a demonstrated hypersensitivity reaction to the drug. Material and methods A 16-year-old male, 85 kg, with severe corticodependent eosinophilic asthma, was admitted for prolonged fever, cholestatic hepatitis, splenomegaly and thrombocytopenia. Visceral leishmaniasis was diagnosed and ANBL treatment was started at 3 mg/kg intravenously (IV) to be administered over 2 hours. During the perfusion the patient presented back pain and headache, which subsided when the perfusion was interrupted. Later, the perfusion was restarted at a slower rate; however, he developed erythematous plaques, discomfort, tachycardia and fever, as a result of which the perfusion was stopped. The ANBL prick test was negative. It has been described that in non-IgE reactions there is a release of cytokines that trigger the symptoms of fever, hypotension, etc. Desensitisation to the antigen produced by the initial cytokine cascade is possible. Second-line alternatives for leishmaniasis were not considered adequate, so it was decided to restart ANBL with a desensitisation protocol, which consisted of administering the drug in three steps, progressively increasing the infusion rate and concentration until administration of the full dose was reached. Low initial doses of antigen produce progressive depletion of activating signals and inhibition of mediator release, thus reducing clinical reactivity. Results In our case, desensitisation consisted of only two steps: 1/10 dilution at a concentration of 0.2 mg/mL (25 mg/ 125mL) and the full dose at 1 mg/mL (250 mg/250mL) of ANBL in 5% glucose serum because there are no stability data for a more dilute preparation of ANBL (1/100). The first dilution was administered in five perfusion rhythms starting at 2.5 mL/hour in 15 min, given good tolerance, the speed was progressively increased every 15 min: 5 mL/hour, 10 mL/hour, 20 mL/hour up to 40 mL/hour. Subsequently, the full dose of ANBL was administered in four rhythms, starting at 10 mL/hour, and increasing to 20 mL/hour, 40 mL/hour to 60 mL/hour, which was maintained until the full dose was reached. Premedication with paracetamol plus IV dexchlorpheniramine was necessary. Conclusion and relevance The use of an ANBL desensitisation protocol has proven to be a safe option, which has allowed the administration of treatment without the appearance of adverse effects.
{"title":"4CPS-027 Desensitisation protocol for liposomal amphothericin B: a case report","authors":"E. Wilhelmi, C. Salazar, R. Farré, M. Duero, A. Machinena, M. Gómez","doi":"10.1136/ejhpharm-2022-eahp.382","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.382","url":null,"abstract":"Background and importance Liposomal amphotericin B (ANBL) is an effective and safe treatment, however non-IgE-mediated hypersensitivity reactions have been described. Aim and objectives To describe the ANBL desensitisation protocol in a patient with leishmaniasis who developed a demonstrated hypersensitivity reaction to the drug. Material and methods A 16-year-old male, 85 kg, with severe corticodependent eosinophilic asthma, was admitted for prolonged fever, cholestatic hepatitis, splenomegaly and thrombocytopenia. Visceral leishmaniasis was diagnosed and ANBL treatment was started at 3 mg/kg intravenously (IV) to be administered over 2 hours. During the perfusion the patient presented back pain and headache, which subsided when the perfusion was interrupted. Later, the perfusion was restarted at a slower rate; however, he developed erythematous plaques, discomfort, tachycardia and fever, as a result of which the perfusion was stopped. The ANBL prick test was negative. It has been described that in non-IgE reactions there is a release of cytokines that trigger the symptoms of fever, hypotension, etc. Desensitisation to the antigen produced by the initial cytokine cascade is possible. Second-line alternatives for leishmaniasis were not considered adequate, so it was decided to restart ANBL with a desensitisation protocol, which consisted of administering the drug in three steps, progressively increasing the infusion rate and concentration until administration of the full dose was reached. Low initial doses of antigen produce progressive depletion of activating signals and inhibition of mediator release, thus reducing clinical reactivity. Results In our case, desensitisation consisted of only two steps: 1/10 dilution at a concentration of 0.2 mg/mL (25 mg/ 125mL) and the full dose at 1 mg/mL (250 mg/250mL) of ANBL in 5% glucose serum because there are no stability data for a more dilute preparation of ANBL (1/100). The first dilution was administered in five perfusion rhythms starting at 2.5 mL/hour in 15 min, given good tolerance, the speed was progressively increased every 15 min: 5 mL/hour, 10 mL/hour, 20 mL/hour up to 40 mL/hour. Subsequently, the full dose of ANBL was administered in four rhythms, starting at 10 mL/hour, and increasing to 20 mL/hour, 40 mL/hour to 60 mL/hour, which was maintained until the full dose was reached. Premedication with paracetamol plus IV dexchlorpheniramine was necessary. Conclusion and relevance The use of an ANBL desensitisation protocol has proven to be a safe option, which has allowed the administration of treatment without the appearance of adverse effects.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"84 7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123120881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.397
A. Corderi Sierra, D. Javier, Bonato Marc, GJ Begonya, SU Azhara, PC Laia, MM Raquel, AJ Veronica, L. David, CB Lluis, Grimes Teresa
{"title":"4CPS-136 Persistence of first-line biological therapy in patients with Crohn’s disease","authors":"A. Corderi Sierra, D. Javier, Bonato Marc, GJ Begonya, SU Azhara, PC Laia, MM Raquel, AJ Veronica, L. David, CB Lluis, Grimes Teresa","doi":"10.1136/ejhpharm-2022-eahp.397","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.397","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125291968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.428
I. Garcia del Valle, G. Morla Clavero, P. Marcos Pacua, N. Joaqui Lopez, M. Garcia Pelaez, G. Baronet Jordana, M. Sanmartín Suñer, L. Val Prat
{"title":"5PSQ-150 Implementation of a program for optimising the use of antibiotics (PROA) in the paediatrics emergency care unit of a third-level hospital","authors":"I. Garcia del Valle, G. Morla Clavero, P. Marcos Pacua, N. Joaqui Lopez, M. Garcia Pelaez, G. Baronet Jordana, M. Sanmartín Suñer, L. Val Prat","doi":"10.1136/ejhpharm-2022-eahp.428","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.428","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"11 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123647853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.408
A. López-García, N. Herranz-Muñoz, I. Salvador-Llana, P. Sanmartín-Fenollera, M. Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C. Martínez-Nieto, A. Onteniente-González, LM Bedoya-del-Olmo, I. Iglesias-Peinado, J. Sánchez-Rubio-Ferrández
{"title":"4CPS-239 Impact of knowledge about human immunodeficiency virus (HIV) transmission on the qualiy of life of people living with HIV","authors":"A. López-García, N. Herranz-Muñoz, I. Salvador-Llana, P. Sanmartín-Fenollera, M. Vélez-Díaz-Pallarés, JA Peña-Pedrosa, C. Martínez-Nieto, A. Onteniente-González, LM Bedoya-del-Olmo, I. Iglesias-Peinado, J. Sánchez-Rubio-Ferrández","doi":"10.1136/ejhpharm-2022-eahp.408","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.408","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129672927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.385
A. Dominguez Barahona, S. Gonzalez Suarez, MA Toledo Davia, C. Blázquez Romero, L. Torralba Fernández, R. López Álvarez, C. Jiménez Méndez, P. Moya Gómez
Background and importanceTocilizumab (TCZ) has been a key pillar in the management of pulmonary hyperinflammation in patients with SARS-CoV-2 pneumonia. The incessant publication of new studies assessing its effectiveness and the ideal time of use means that in-hospital protocols are constantly being reviewed and updated.Aim and objectivesTo describe the clinical characteristics of hospitalised patients with SARS-CoV-2 pneumonia treated with TCZ and their evolution, and to compare our results with those of the primary endpoint (28-day mortality) of the RECOVERY study.Material and methodsRetrospective observational study of patients administered TCZ between October 2020 and February 2021 in a tertiary hospital. Criteria for TCZ use were PAFI <300 and meeting two of the following three criteria: C-reactive protein (CRP) >150 mg/L, D-dimer >1500 ng/mL and ferritin >2000 ng/mL, and not having contraindications for its use.Each patient received a single dose of 400 mg if weight <75 kg and 600 mg if weight >75 kg.Demographic data, comorbidities and days from symptom onset to TCZ administration were collected. Follow-up of analytical data (CRP, D-dimer and ferritin pre- and post- (15 days) TCZ administration). Clinical evolution was evaluated by mortality rate at 28 days.Statistical analysis: Stata/MP v16.0. Student’s t-test was used for comparison of quantitative variables.Results39 patients were included, 25 (64.1%) were male, median age 74 (IQR 61–80) years. 61.5% had hypertension, 33.3% obesity, 41% diabetes mellitus, 17.9% chronic kidney disease, 12.8% heart disease. The median time from symptom onset to TCZ administration was 10 (IQR 7–15) days.The medians prior to and at 15 days of TCZ administration were, respectively: 152.5 mg/L (IQR 89–220.8) and 1.7 mg/L (IQR 0.65–4.2) CRP (p<0.001);2300 ng/mL (IQR 11 959–4889) and 1124 ng/mL (IQR 567–1439) D-dimer (p=0.1726);1242 ng/mL (IQR 647–2705) and 851 ng/mL (IQR 268–1384) ferritin (p=0.1294). Mortality at 28 days was 64.1%.Conclusion and relevanceOur sample size is smaller than that of the RECOVERY study;however, the days of symptoms until TCZ administration (10 vs 9) and the median CRP prior to TCZ (143 vs 152.5 mg/L) in both studies are very similar. Our mortality is much higher (64.1% vs 29%). We found a statistically significant difference between our pre- and post-CRP data.With this result, the in-hospital protocol was modified and new criteria for TCZ administration in COVID patients became oxygen saturation <92% or PAFI >300 and CRP >75 mg/L, with no contraindications for use.In subsequent studies we will test whether this update helps to improve mortality outcomes.References and/or acknowledgementsConflict of interestNo conflict of interest
{"title":"4CPS-036 Is our protocol for the use of tocilizumab in COVID patients adequate?","authors":"A. Dominguez Barahona, S. Gonzalez Suarez, MA Toledo Davia, C. Blázquez Romero, L. Torralba Fernández, R. López Álvarez, C. Jiménez Méndez, P. Moya Gómez","doi":"10.1136/ejhpharm-2022-eahp.385","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.385","url":null,"abstract":"Background and importanceTocilizumab (TCZ) has been a key pillar in the management of pulmonary hyperinflammation in patients with SARS-CoV-2 pneumonia. The incessant publication of new studies assessing its effectiveness and the ideal time of use means that in-hospital protocols are constantly being reviewed and updated.Aim and objectivesTo describe the clinical characteristics of hospitalised patients with SARS-CoV-2 pneumonia treated with TCZ and their evolution, and to compare our results with those of the primary endpoint (28-day mortality) of the RECOVERY study.Material and methodsRetrospective observational study of patients administered TCZ between October 2020 and February 2021 in a tertiary hospital. Criteria for TCZ use were PAFI <300 and meeting two of the following three criteria: C-reactive protein (CRP) >150 mg/L, D-dimer >1500 ng/mL and ferritin >2000 ng/mL, and not having contraindications for its use.Each patient received a single dose of 400 mg if weight <75 kg and 600 mg if weight >75 kg.Demographic data, comorbidities and days from symptom onset to TCZ administration were collected. Follow-up of analytical data (CRP, D-dimer and ferritin pre- and post- (15 days) TCZ administration). Clinical evolution was evaluated by mortality rate at 28 days.Statistical analysis: Stata/MP v16.0. Student’s t-test was used for comparison of quantitative variables.Results39 patients were included, 25 (64.1%) were male, median age 74 (IQR 61–80) years. 61.5% had hypertension, 33.3% obesity, 41% diabetes mellitus, 17.9% chronic kidney disease, 12.8% heart disease. The median time from symptom onset to TCZ administration was 10 (IQR 7–15) days.The medians prior to and at 15 days of TCZ administration were, respectively: 152.5 mg/L (IQR 89–220.8) and 1.7 mg/L (IQR 0.65–4.2) CRP (p<0.001);2300 ng/mL (IQR 11 959–4889) and 1124 ng/mL (IQR 567–1439) D-dimer (p=0.1726);1242 ng/mL (IQR 647–2705) and 851 ng/mL (IQR 268–1384) ferritin (p=0.1294). Mortality at 28 days was 64.1%.Conclusion and relevanceOur sample size is smaller than that of the RECOVERY study;however, the days of symptoms until TCZ administration (10 vs 9) and the median CRP prior to TCZ (143 vs 152.5 mg/L) in both studies are very similar. Our mortality is much higher (64.1% vs 29%). We found a statistically significant difference between our pre- and post-CRP data.With this result, the in-hospital protocol was modified and new criteria for TCZ administration in COVID patients became oxygen saturation <92% or PAFI >300 and CRP >75 mg/L, with no contraindications for use.In subsequent studies we will test whether this update helps to improve mortality outcomes.References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116833853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.391
A. de Lorenzo-Pinto, C. Ortega-Navararo, B. Torroba-Sanz, C. Fernandez-Llamazares, I. Taladriz-Sender, A. Herranz-Alonso, M. Sanjurjo-Sáez
{"title":"4CPS-095 Appropriateness of empirical antibiotic therapy for cervicitis and urethritis prescribed at the emergency department","authors":"A. de Lorenzo-Pinto, C. Ortega-Navararo, B. Torroba-Sanz, C. Fernandez-Llamazares, I. Taladriz-Sender, A. Herranz-Alonso, M. Sanjurjo-Sáez","doi":"10.1136/ejhpharm-2022-eahp.391","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.391","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131815364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.404
M. Gutiérrez Lorenzo, M. F. Fernández Gonzalez, P. Ciudad Gutiérrez, P. del Valle Moreno
{"title":"4CPS-199 Evaluation of fremanezumab response in migraine prophylaxis","authors":"M. Gutiérrez Lorenzo, M. F. Fernández Gonzalez, P. Ciudad Gutiérrez, P. del Valle Moreno","doi":"10.1136/ejhpharm-2022-eahp.404","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.404","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"182 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114956900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01DOI: 10.1136/ejhpharm-2022-eahp.427
C. Ortega Navarro, A. de Lorenzo Pinto, R. García Sánchez, B. Torroba Sanz, A. Herranz Alonso, M. Sanjurjo Sáez
{"title":"5PSQ-148 TANDEM project: transitions of care and medication reconciliation in high-risk patients","authors":"C. Ortega Navarro, A. de Lorenzo Pinto, R. García Sánchez, B. Torroba Sanz, A. Herranz Alonso, M. Sanjurjo Sáez","doi":"10.1136/ejhpharm-2022-eahp.427","DOIUrl":"https://doi.org/10.1136/ejhpharm-2022-eahp.427","url":null,"abstract":"","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131135170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：